Changes in oxidative stress and microcirculation by low-density lipoprotein apheresis

Therapeutic Apheresis

Volumn 7, Issue 4, 2003, Pages 419-424

  Sato, Motoyoshi ^a   Amano, Izumi ^a  

^a CHUKYO HOSPITAL   (Japan)

Author keywords

Dextran sulfate adsorption LDL apheresis; Endothelial dysfunction; Low density lipoprotein apheresis; Microcirculation; Oxidative stress

Indexed keywords

DEXTRAN SULFATE; LOW DENSITY LIPOPROTEIN;

ADSORPTION; APHERESIS; ARTERY DISEASE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD RHEOLOGY; DISEASE COURSE; ENDOTHELIUM; HUMAN; MICROCIRCULATION; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

ARTERIAL OCCLUSIVE DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPOPROTEINS, LDL; MALE; MICROCIRCULATION; OXIDATIVE STRESS; PERIPHERAL VASCULAR DISEASES; PLASMAPHERESIS; RENAL DIALYSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 0042316781     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.2003.00078.x     Document Type: Review

References (25)

1. Koga N, Iwata Y. Pathologocal and angiographic regression of coronary atherosclerosis by LDL-apheresis in a patient with familial hypercholesterolemia. Atherosclerosis 1991:90:9-21.
2. Agishi T, Naganuma S, Nakasato S et al. Treatment of arteriosclerotic obstruction by LDL adsorption. Angiology 1993;44:222-7.
3. Yokoyama S, Hayashi R, Satani M, Yamamoto A. Selective removal of low-density lipoprotein by plasmapheresis in familial hypercholesterolemia. Atherosclerosis 1985;5:613-22.
4. Stoffel W, Borberg H, Greve V. Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolemia. Lancet 1981;ii:1005-7.
5. Eisenhauer T, Armstrong VW, Wieland H et al. Selective continuous elimination of low-density lipoprotein (LDL) heparin precipitation: first clinical application. ASAIO Trans 1986;32:104-7.
6. Bosch T, Schmidt B, Kleophas W, Otto V, Samtleber W. LDL hemoperfusion - a new procedure for LDL apheresis: first clinical application of an LDL adsorber compatible with human whole blood. Artif Organs 1997;21:977-82.
7. Komiyama T, Shigematsu H, Yasuhara H, Muto T. An objective assessment of intermittent claudication by near-infrared spectroscopy. Eur J Vasc Surg 1994;8:294-6.
8. Rubba P, Iannuzzi A, Postiglione A et al. Hemodynamic changes in the peripheral circulation after repeat low density lipoprotein apheresis in familial hypercholesterolemia. Circulation 1990;81:610-6.
9. Kojima S, Harada-Shiba M, Toyota Y et al. Change in coagulation factors by passage through a dextran sulfate cellulose column during low-density lipoprotein apheresis. Int J Artif Organs 1992;15:185-90.
10. Knisel W, Di Nicuolo A, Pfohl M et al. Different effects of two methods of low-density lipoprotein apheresis on the coagulation and fibrinolytic systems. J Int Med 1993;234:479-87.
11. Murashima J, Ueki Y, Matsunaga Y et al. Removal of low-density lipoprotein from plasma by adsorption increases bradykinin and plasma nitric oxide levels in patients with periphera atherosclerosis. Blood Coag Fibrinol 1998;9:725-32.
12. Kizaki Y, Ueki Y, Yoshida K et al. Does the production of nitric oxide contribute to the early improvement after a single low-density lipoprotein apheresis in patients with peripheral arterial obstructive disease? Blood Coag Fibrinol 1999;10:341-9.
13. Mii S, Mori A, Sakata H, Nakayama M, Tsuruta H. LDL apheresis for arteriosclerosis obliterans with occluded bypass graft: change in prostacyclin and effect on ischemic symptoms. Angiology 1998;49:175-80.
14. Ross R. Atherosclerosis - an inflammatory disease. New Engl J Med 1999;340:115-26.
15. Uno H, Ueki Y, Murashima J et al. Removal of LDL from plasma by adsorption reduced adhesion molecules on mononuclear cells in patients with arteriosclerotic obliterance. Atherosclerosis 1995;116:93-102.
16. Rovers C, Netea MG, de Bont N et al. LPS-induced cytokine production and expression of β2-integrins and CD14 by peripheral blood mononuclear cells of patients with homozygous familial hypercholesterolemia. Atherosclerosis 1998;141:99-105.
17. Leitinger N, Pirich C, Blazek I, Endler G, Sinzinger H. Decreased susceptibility of low-density lipoproteins to in-vitro oxidation after dextran-sulfate LDL-apheresis treatment. Atherosclerosis 1996;126:305-12.
18. Inoue I, Takahashi K, Kikuchi C, Katayama S. LDL apheresis reduces the susceptibility of LDL to in vitro oxidation in a diabetic patients with hemodialysis treatment. Diabetes Care 1996;19:1103-7.
19. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997;95:76-82.
20. Gerard ML, Tilman BD. Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 1997;51:1678-95.
21. Tomura S, Nakamura Y, Deguchi F et al. Plasma von Willebrand factor and thrombomodulin as markers of vascular disorders in patients undergoing hemodialysis. Thromb Res 1990;58:4134-9.
22. Agishi T, Nakasato S, Ota K. Prognosis of patients with arteriosclerosis obliterans treated with LDL-apheresis. Vasc Surg 1994;28:513-7.
23. Kroon AA, van Asten WNJC, Stalenhoef AFH. Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann Intern Med 1996;125:945-54.
24. Reddan DN, Marcus RJ, Owen Jr. WF, Szczech LA, Landwehr DM. Long-term outcomes of revascularization for peripheral vascular disease in end-stage renal disease patients. Am J Kidney Dis 2001;38:57-63.
25. Kajinami K, Mabuchi H. Therapeutic effects of LDL apheresis in the prevention of atherosclerosis. Curr Opin Lipidol 1999;10:401-6.